FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367676768> ?p ?o ?g. }

• W4367676768 abstract "Abstract BACKGROUND A subset of triple-negative breast cancers (TNBCs) have homologous recombination deficiency with upregulation of compensatory DNA repair pathways. PIKTOR, a combination of TAK-228 (TORC1/2 inhibitor) and TAK-117 (PI3Kα inhibitor), is hypothesized to increase genomic instability and increase DNA damage repair (DDR) deficiency, leading to increased sensitivity to DNA-damaging chemotherapy and to immune checkpoint blockade inhibitors. METHODS 10 metastatic TNBC patients received 4mg TAK-228 and 200mg TAK-117 (PIKTOR) orally each day for 3 days followed by 4 days off, weekly, until disease progression (PD), followed by intravenous cisplatin 75 mg/m 2 plus nab paclitaxel 220 mg/m 2 every 3 weeks for up to 6 cycles. Patients received subsequent treatment with pembrolizumab and/or chemotherapy. Primary endpoints were objective response rate with cisplatin/nab paclitaxel and safety. Biopsies of a metastatic lesion were collected prior to and at PD on PIKTOR. Whole exome and RNA-sequencing and reverse phase protein arrays (RPPA) were used to phenotype tumors pre- and post-PIKTOR for alterations in DDR, proliferation, and immune response. RESULTS With cisplatin/nab paclitaxel (cis/nab pac) therapy post PIKTOR, 3 patients had clinical benefit (1 partial response (PR) and 2 stable disease (SD) ≥ 6 months) and continued to have durable benefit in progression-free survival with pembrolizumab post-cis/nab pac for 1.2, 2, and 3.6 years. Their post-PIKTOR metastatic tissue displayed decreased mismatch repair (MMR), increased tumor mutation burden, and significantly lower levels of 53BP1, DAG Lipase β, GCN2, AKT Ser473, and PKCzeta Thr410/403 compared to pre-PIKTOR tumor tissue. CONCLUSIONS Priming patients’ chemotherapy-pretreated metastatic TNBC with PIKTOR led to very prolonged response/disease control with subsequent cis/nab pac, followed by pembrolizumab, in 3 of 10 treated patients. Our multi-omics approach revealed a higher number of genomic alterations, reductions in MMR, and alterations in immune and stress response pathways post-PIKTOR in patients who had durable responses. TRIAL REGISTRATION This clinical trial was registered on June 21, 2017, at ClinicalTrials.gov using identifier NCT03193853." @default.
• W4367676768 created "2023-05-03" @default.
• W4367676768 creator A5000330909 @default.
• W4367676768 creator A5010670090 @default.
• W4367676768 creator A5011429909 @default.
• W4367676768 creator A5018256290 @default.
• W4367676768 creator A5021856839 @default.
• W4367676768 creator A5024100563 @default.
• W4367676768 creator A5032266492 @default.
• W4367676768 creator A5033171342 @default.
• W4367676768 creator A5035185963 @default.
• W4367676768 creator A5037609818 @default.
• W4367676768 creator A5047279354 @default.
• W4367676768 creator A5051099531 @default.
• W4367676768 creator A5071432873 @default.
• W4367676768 creator A5083426638 @default.
• W4367676768 date "2023-05-02" @default.
• W4367676768 modified "2023-09-27" @default.
• W4367676768 title "Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel" @default.
• W4367676768 cites W1520425169 @default.
• W4367676768 cites W1528367896 @default.
• W4367676768 cites W1996931025 @default.
• W4367676768 cites W2063382533 @default.
• W4367676768 cites W2072651545 @default.
• W4367676768 cites W2092462528 @default.
• W4367676768 cites W2097539177 @default.
• W4367676768 cites W2109882948 @default.
• W4367676768 cites W2114860131 @default.
• W4367676768 cites W2119583721 @default.
• W4367676768 cites W2120806256 @default.
• W4367676768 cites W2128916321 @default.
• W4367676768 cites W2130084494 @default.
• W4367676768 cites W2132966617 @default.
• W4367676768 cites W2144977086 @default.
• W4367676768 cites W2145122380 @default.
• W4367676768 cites W2145722025 @default.
• W4367676768 cites W2146917785 @default.
• W4367676768 cites W2165385395 @default.
• W4367676768 cites W2325555899 @default.
• W4367676768 cites W2394944900 @default.
• W4367676768 cites W2402636472 @default.
• W4367676768 cites W2409012376 @default.
• W4367676768 cites W2415215726 @default.
• W4367676768 cites W2478157071 @default.
• W4367676768 cites W2564136012 @default.
• W4367676768 cites W2586472040 @default.
• W4367676768 cites W2614952490 @default.
• W4367676768 cites W2755795896 @default.
• W4367676768 cites W2773427199 @default.
• W4367676768 cites W2779333875 @default.
• W4367676768 cites W2890266060 @default.
• W4367676768 cites W2891429805 @default.
• W4367676768 cites W2898861270 @default.
• W4367676768 cites W2913788177 @default.
• W4367676768 cites W2915710933 @default.
• W4367676768 cites W2943363006 @default.
• W4367676768 cites W2946269255 @default.
• W4367676768 cites W2958725515 @default.
• W4367676768 cites W2979370542 @default.
• W4367676768 cites W3012440210 @default.
• W4367676768 cites W3040050969 @default.
• W4367676768 cites W3110525700 @default.
• W4367676768 cites W3120381370 @default.
• W4367676768 cites W3134025815 @default.
• W4367676768 cites W3135041256 @default.
• W4367676768 cites W3164153014 @default.
• W4367676768 cites W3170283419 @default.
• W4367676768 cites W4220976545 @default.
• W4367676768 cites W4283790062 @default.
• W4367676768 cites W4284895928 @default.
• W4367676768 cites W4285743613 @default.
• W4367676768 cites W4320725227 @default.
• W4367676768 doi "https://doi.org/10.21203/rs.3.rs-2864312/v1" @default.
• W4367676768 hasPublicationYear "2023" @default.
• W4367676768 type Work @default.
• W4367676768 citedByCount "0" @default.
• W4367676768 crossrefType "posted-content" @default.
• W4367676768 hasAuthorship W4367676768A5000330909 @default.
• W4367676768 hasAuthorship W4367676768A5010670090 @default.
• W4367676768 hasAuthorship W4367676768A5011429909 @default.
• W4367676768 hasAuthorship W4367676768A5018256290 @default.
• W4367676768 hasAuthorship W4367676768A5021856839 @default.
• W4367676768 hasAuthorship W4367676768A5024100563 @default.
• W4367676768 hasAuthorship W4367676768A5032266492 @default.
• W4367676768 hasAuthorship W4367676768A5033171342 @default.
• W4367676768 hasAuthorship W4367676768A5035185963 @default.
• W4367676768 hasAuthorship W4367676768A5037609818 @default.
• W4367676768 hasAuthorship W4367676768A5047279354 @default.
• W4367676768 hasAuthorship W4367676768A5051099531 @default.
• W4367676768 hasAuthorship W4367676768A5071432873 @default.
• W4367676768 hasAuthorship W4367676768A5083426638 @default.
• W4367676768 hasBestOaLocation W43676767681 @default.
• W4367676768 hasConcept C104317684 @default.
• W4367676768 hasConcept C121608353 @default.
• W4367676768 hasConcept C126322002 @default.
• W4367676768 hasConcept C134935766 @default.
• W4367676768 hasConcept C143998085 @default.
• W4367676768 hasConcept C182979987 @default.
• W4367676768 hasConcept C2775930923 @default.
• W4367676768 hasConcept C2776694085 @default.

• next